---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-031189"
form_type: "8-K"
ticker: "ONCO"
cik: "0001782107"
company_name: "Onconetix, Inc."
filed_at: "2023-04-20T23:59:59+00:00"
generated_at: "2026-06-16T22:39:44.080239+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Blue Water Vaccines acquires Veru's ENTADFI for $100M; plans name change to Blue Water Biotech

## Summary
- Total consideration $100M: $20M upfront (tranches through Sept 2024) plus up to $80M in sales milestones.
- Assumes royalty and milestone obligations up to $22.5M from prior agreement.
- Acquires ~125,000 bottles of ENTADFI, an FDA-approved BPH treatment.
- Company will change name to Blue Water Biotech; CEO Joseph Hernandez leads.
- Frank Jaeger to lead commercialization; previously doubled AndroGel sales to $1.3B.

## SEC filing metadata
- accession: 0001213900-23-031189
- form_type: 8-K
- ticker: ONCO
- cik: 0001782107
- company_name: Onconetix, Inc.
- filed_at: 2023-04-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782107/000121390023031189/0001213900-23-031189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782107/000121390023031189/ea177216-8k_bluewater.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-031189
- JSON: https://secwatch.observer/filing/0001213900-23-031189.json
- Plain text: https://secwatch.observer/filing/0001213900-23-031189.txt

## Key facts
- M&A Transactions
  Onconetix, Inc. completed an acquisition involving Veru Inc. for $100,000,000 (closed 2023-04-19).
  - Action: acquisition
  - Counterparty: Veru Inc.
  - Consideration: $100,000,000
  - Closing: 2023-04-19
  source text: of the Transaction The Company purchased substantially all of the Seller’s assets, rights and property related to the ENTADFI TM Business for a total possible consideration of $100,000,000 (as described below). The ENTADFI TM Business capitalizes on the demonstrable success of the FDA-approved drug ENTADFI TM for treating benign prostatic hyperplasia and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782107/000121390023031189/0001213900-23-031189-index.htm
- Material Agreements
  Onconetix, Inc. entered into Purchase Agreement with Veru Inc. valued at total possible consideration of $100,000,000 (effective 2023-04-19).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Veru Inc.
  - Value: total possible consideration of $100,000,000
  - Effective: 2023-04-19
  source text: On April 19, 2023, Blue Water Vaccines Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the "Purchase Agreement") with Veru Inc., a Wisconsin corporation (the "Seller").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782107/000121390023031189/0001213900-23-031189-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.